Effect of adjunctive glucose-lowering drugs on body weight in people with type 1 diabetes: a systematic review and network meta-analysis protocol

Introduction Obesity increases the risk of comorbidities and diabetes-related complications and, consequently, efforts to prevent and reduce excess weight in people with type 1 diabetes are essential. The aim of this systematic review and network meta-analysis is to assess the effect of adjunctive g...

Full description

Bibliographic Details
Main Authors: Christian Laugesen, Ajenthen G. Ranjan, Signe Schmidt, Lauge Neimann Rasmussen, Ole Nørgaard
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/11/e038970.full
id doaj-19834ef425874ebd927c7f60df1426ad
record_format Article
spelling doaj-19834ef425874ebd927c7f60df1426ad2021-06-25T12:34:45ZengBMJ Publishing GroupBMJ Open2044-60552020-11-01101110.1136/bmjopen-2020-038970Effect of adjunctive glucose-lowering drugs on body weight in people with type 1 diabetes: a systematic review and network meta-analysis protocolChristian Laugesen0Ajenthen G. Ranjan1Signe Schmidt2Lauge Neimann Rasmussen3Ole Nørgaard4Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, DenmarkClinical Research, Steno Diabetes Center Copenhagen, Gentofte, DenmarkDiabetes Technology, Steno Diabetes Center Copenhagen, Gentofte, DenmarkEducation, Diabetes Knowledge Center, Steno Diabetes Center Copenhagen, Gentofte, DenmarkEducation, Diabetes Knowledge Center, Steno Diabetes Center Copenhagen, Gentofte, DenmarkIntroduction Obesity increases the risk of comorbidities and diabetes-related complications and, consequently, efforts to prevent and reduce excess weight in people with type 1 diabetes are essential. The aim of this systematic review and network meta-analysis is to assess the effect of adjunctive glucose-lowering drugs on body weight and other important health outcomes in people with type 1 diabetes.Methods and analysis This systematic review and network meta-analysis will include randomised controlled trials (RCTs) evaluating the use of adjunctive glucose-lowering drugs for treatment of people with type 1 diabetes. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, ClinicalTrials.gov and WHO International Clinical Trials Registry Platform will be searched from inception to present. Key eligibility criteria include: RCT study design; adult participants with type 1 diabetes; treatment with a glucose-lowering drug for ≥24 weeks; and comparison of the intervention to placebo, usual care or another glucose-lowering drug. The primary outcome is change in body weight. Other major outcomes include change in HbA1c and total daily insulin dose and risk of hypoglycaemia and other adverse events. Dual study selection, data extraction and risk of bias assessment will be performed. Results from the meta-analysis will be presented as weighted mean differences for continuous outcomes and risk ratios for dichotomous outcomes. Sources of heterogeneity will be explored by subgroup and sensitivity analysis. A network meta-analysis for the primary outcome will be performed using an arm-based random-effects model based on the Bayesian framework while assessing for transitivity across studies and consistency between direct and indirect estimates. The overall quality of the evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach for each outcome.Ethics and dissemination No ethical assessment is required. The results of this review will be disseminated through peer-reviewed publication and conference presentation.PROSPERO registration number CRD42020158676https://bmjopen.bmj.com/content/10/11/e038970.full
collection DOAJ
language English
format Article
sources DOAJ
author Christian Laugesen
Ajenthen G. Ranjan
Signe Schmidt
Lauge Neimann Rasmussen
Ole Nørgaard
spellingShingle Christian Laugesen
Ajenthen G. Ranjan
Signe Schmidt
Lauge Neimann Rasmussen
Ole Nørgaard
Effect of adjunctive glucose-lowering drugs on body weight in people with type 1 diabetes: a systematic review and network meta-analysis protocol
BMJ Open
author_facet Christian Laugesen
Ajenthen G. Ranjan
Signe Schmidt
Lauge Neimann Rasmussen
Ole Nørgaard
author_sort Christian Laugesen
title Effect of adjunctive glucose-lowering drugs on body weight in people with type 1 diabetes: a systematic review and network meta-analysis protocol
title_short Effect of adjunctive glucose-lowering drugs on body weight in people with type 1 diabetes: a systematic review and network meta-analysis protocol
title_full Effect of adjunctive glucose-lowering drugs on body weight in people with type 1 diabetes: a systematic review and network meta-analysis protocol
title_fullStr Effect of adjunctive glucose-lowering drugs on body weight in people with type 1 diabetes: a systematic review and network meta-analysis protocol
title_full_unstemmed Effect of adjunctive glucose-lowering drugs on body weight in people with type 1 diabetes: a systematic review and network meta-analysis protocol
title_sort effect of adjunctive glucose-lowering drugs on body weight in people with type 1 diabetes: a systematic review and network meta-analysis protocol
publisher BMJ Publishing Group
series BMJ Open
issn 2044-6055
publishDate 2020-11-01
description Introduction Obesity increases the risk of comorbidities and diabetes-related complications and, consequently, efforts to prevent and reduce excess weight in people with type 1 diabetes are essential. The aim of this systematic review and network meta-analysis is to assess the effect of adjunctive glucose-lowering drugs on body weight and other important health outcomes in people with type 1 diabetes.Methods and analysis This systematic review and network meta-analysis will include randomised controlled trials (RCTs) evaluating the use of adjunctive glucose-lowering drugs for treatment of people with type 1 diabetes. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, ClinicalTrials.gov and WHO International Clinical Trials Registry Platform will be searched from inception to present. Key eligibility criteria include: RCT study design; adult participants with type 1 diabetes; treatment with a glucose-lowering drug for ≥24 weeks; and comparison of the intervention to placebo, usual care or another glucose-lowering drug. The primary outcome is change in body weight. Other major outcomes include change in HbA1c and total daily insulin dose and risk of hypoglycaemia and other adverse events. Dual study selection, data extraction and risk of bias assessment will be performed. Results from the meta-analysis will be presented as weighted mean differences for continuous outcomes and risk ratios for dichotomous outcomes. Sources of heterogeneity will be explored by subgroup and sensitivity analysis. A network meta-analysis for the primary outcome will be performed using an arm-based random-effects model based on the Bayesian framework while assessing for transitivity across studies and consistency between direct and indirect estimates. The overall quality of the evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach for each outcome.Ethics and dissemination No ethical assessment is required. The results of this review will be disseminated through peer-reviewed publication and conference presentation.PROSPERO registration number CRD42020158676
url https://bmjopen.bmj.com/content/10/11/e038970.full
work_keys_str_mv AT christianlaugesen effectofadjunctiveglucoseloweringdrugsonbodyweightinpeoplewithtype1diabetesasystematicreviewandnetworkmetaanalysisprotocol
AT ajenthengranjan effectofadjunctiveglucoseloweringdrugsonbodyweightinpeoplewithtype1diabetesasystematicreviewandnetworkmetaanalysisprotocol
AT signeschmidt effectofadjunctiveglucoseloweringdrugsonbodyweightinpeoplewithtype1diabetesasystematicreviewandnetworkmetaanalysisprotocol
AT laugeneimannrasmussen effectofadjunctiveglucoseloweringdrugsonbodyweightinpeoplewithtype1diabetesasystematicreviewandnetworkmetaanalysisprotocol
AT olenørgaard effectofadjunctiveglucoseloweringdrugsonbodyweightinpeoplewithtype1diabetesasystematicreviewandnetworkmetaanalysisprotocol
_version_ 1721359757321699328